| Literature DB >> 30268501 |
Yutaka Deguchi1, Takashi Nishina2, Kenichi Asano3, Masaki Ohmuraya4, Yoshiko Nakagawa5, Naomi Nakagata5, Tetsushi Sakuma6, Takashi Yamamoto6, Kimi Araki7, Tetuo Mikami8, Masato Tanaka3, Hiroyasu Nakano9.
Abstract
Interleukin (IL)-11 belongs to the members of the IL-6 family of cytokines and is involved in a variety of biological responses, including hematopoiesis, bone development, and carcinogenesis. However, the cellular sources of IL-11 and regulation of IL-11 expression under physiological and pathological conditions are not fully understood. One of the causes to prevent characterization of IL-11 in vivo is due to the lack of reliable antibodies that detect IL-11 by immunohistochemistry. Moreover, although mice lacking Il11ra have been generated and extensively characterized, Il11-deficient mice have not been characterized yet. Here we generated two anti-IL-11 antibodies that blocked biological activities of IL-11 and detected IL-11 by immunohistochemistry, respectively. One clone of anti-IL-11 antibodies blocked IL-11-, but not IL-6-induced cell proliferation and IL-11-induced phosphorylation of STAT3 of an IL-11-dependent cell line. Moreover, we used recently established Il11-deficient mice to test the specificity of anti-IL-11 antibodies for immunohistochemistry. Another clone of anti-IL-11 antibodies stained stromal cells surrounding tumors of the colon of wild-type, but not Il11-deficient mice following treatment with Azoxymethane plus dextran sulfate sodium. Together, these newly developed anti-IL-11 antibodies provide a better understanding of the functions of IL-11 in vivo under various physiological and pathological conditions.Entities:
Keywords: CRISPR-Cas9; Interleukin 11; Knockout mice; Proliferation; STAT3
Mesh:
Substances:
Year: 2018 PMID: 30268501 DOI: 10.1016/j.bbrc.2018.09.128
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575